BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2021

Apr 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2021-04-22

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-22	Common Stock	M	10000	$26.49	Acquired	312498	Direct
2021-04-22	Common Stock	S	10000	$78.91	Disposed	302498	Direct
2021-04-23	Common Stock	M	10000	$26.49	Acquired	312498	Direct
2021-04-23	Common Stock	S	10000	$79.34	Disposed	302498	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-22	Stock Option (Right to buy Common Stock)	$26.49	M	10000	Disposed	2021-05-11	Common Stock (10000)	Direct
2021-04-23	Stock Option (Right to buy Common Stock)	$26.49	M	10000	Disposed	2021-05-11	Common Stock (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	247533	Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021.

F2: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $77.9400 on March 4, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.

F3: Reflects the number of options outstanding after the transactions from this specific stock option grant.